Peptide Coacervates as Dynamic and Interactive Depots for Tetrodotoxin in Long-Acting Local Anesthesia.
Summary
This mechanistic and translational study developed a mussel foot protein-inspired peptide coacervate that binds tetrodotoxin through multivalent noncovalent interactions and enables sustained release. In rats, the formulation prolonged sensory nerve blockade to 10.5 hours and reduced systemic toxicity 1.5-fold compared with tetrodotoxin alone, while molecular simulations supported the proposed hydrogen-bonding mechanism.
Key Findings
- Mfp3s-pep spontaneously formed coacervates under physiological conditions and sequestered 29% of tetrodotoxin.
- The tetrodotoxin–Mfp3s-pep formulation prolonged sensory blockade in a rat sciatic nerve model to 10.5 hours.
- The formulation reduced systemic toxicity 1.5-fold compared with tetrodotoxin alone, with molecular modeling supporting dynamic hydrogen-bonding interactions.
Clinical Implications
The platform could eventually support longer-lasting single-injection nerve blocks and reduce systemic toxicity, but clinical use requires extensive toxicology, reproducibility, dose optimization, and human safety testing.
Why It Matters
The work addresses a central limitation of long-acting local anesthesia: delivering highly water-soluble molecules without sacrificing potency or safety. It combines materials engineering, molecular mechanism, and in vivo regional anesthesia in a platform with potential applicability beyond tetrodotoxin.
Limitations
- The evidence is preclinical and was generated in a rat sciatic nerve block model.
- Long-term neurotoxicity, immunogenicity, pharmacokinetics, manufacturing scalability, and human safety were not established.
Future Directions
Future studies should define dose–response relationships, tissue distribution, duration of sensory and motor block, repeat-dose safety, neurotoxicity, and efficacy in larger animal models before considering first-in-human studies.
Study Information
- Study Type
- Basic/Mechanistic study
- Research Domain
- Treatment
- Evidence Level
- V - Preclinical experimental study with mechanistic characterization and in vivo animal validation.
- Study Design
- OTHER